The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene

Blood

Volumn 112, Issue 10, 2008, Pages 4184-4192

  Wang, Pin Yi ^a   Young, Fay ^b,c   Chen, Chun Yu ^d   Stevens, Brett M ^c   Neering, Sarah J ^c   Rossi, Randall M ^c   Bushnell, Timothy ^c   Kuzin, Igor ^c   Heinrich, David ^c   Bottaro, Andrea ^c   Jordan, Craig T ^b,c  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b Division of Hematology/Oncology   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d University of Rochester   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; PROTEIN P19; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; HEMATOPOIETIC STEM CELL; LEUKEMOGENESIS; LYMPHOID PROGENITOR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR SUPPRESSOR GENE; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; FUSION PROTEINS, BCR-ABL; LYMPHOID PROGENITOR CELLS; MICE; MICE, TRANSGENIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 58149176136     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-142190     Document Type: Article

References (31)

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645- 648.
2. Cozzio A PE, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and shortlived myeloid progenitors. Genes Dev. 2003;17: 3029-3035.
3. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZTIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587-596.
4. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442: 818-822.
5. Neering SJ, Bushnell T, Sozer S, et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007;110:2578-2585.
6. Castor A, Nilsson L, Astrand-Grundstrom I, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med. 2005;11:630-637.
7. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia- positive acute lymphoblastic leukemia. Blood. 2000;95:1007-1013.
8. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cell. Blood. 2004;104:2919-2925.
9. George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood. 2001;97: 3925-3930.
10. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022.
11. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013-2016.
12. Hernandez-Boluda JC, Cervantes F, Colomer D, et al. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol. 2003;31:204-210.
13. Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008;22:1411- 1415.
14. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 2001;413:86-91.
15. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 2001; 413:83-86.
16. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996; 85:27-37.
17. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649-659.
18. Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A. 1998;95:13194-13199.
19. Mostecki J, Halgren A, Radfar A, et al. Loss of heterozygosity at the Ink4a/Arf locus facilitates Abelson virus transformation of pre-B cells. J Virol. 2000;74:9479-9487.
20. Randle DH, Zindy F, Sherr CJ, Roussel MF. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci U S A. 2001;98:9654-9659.
21. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2006;103:6688-6693.
22. Williams RT, den Besten W, Sherr CJ. Cytokinedependent imatinib resistance in mouse BCRABL +, Arf-null lymphoblastic leukemia. Genes Dev. 2007;21:2283-2287.
23. Van Etten RA. Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol Dis. 2001;27:201-205.
24. Ponzetto C, Guerrasio A, Rosso C, et al. ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. Br J Haematol. 1990;76:39-44.
25. Li S, Ilaria RL, Jr., Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity. J Exp Med. 1999;189:1399-1412.
26. Whetton AD, Graham GJ. Homing and mobilization in the stem cell niche. Trends Cell Biol. 1999; 9:233-238.
27. Suda T, Arai F, Hirao A. Hematopoietic stem cells and their niche. Trends Immunol. 2005;26:426- 433.
28. Hardy RR, Kincade PW, Dorshkind K. The protean nature of cells in the B lymphocyte lineage. Immunity. 2007;26:703-714.
29. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311-321.
30. Shank-Calvo JA, Draheim K, Bhasin M, Kelliher MA. p16Ink4a or p19Arf loss contributes to Tal1- induced leukemogenesis in mice. Oncogene. 2006;25:3023-3031.
31. Kohno T, Yamada Y, Tawara M, et al. Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leuk Res. 2007; 31:1625-1632.